It's the second drug in the TFPI class to be approved by the FDA after Pfizer's once-weekly Hympavzi (marstacimab), cleared in October for haemophilia A and B without inhibitors, and has also been ...

In its second attempt, Takeda has secured FDA approval for Eohilia ... oral suspension formulation of the well-established steroid drug budesonide, for people 11 years and older with EoE after ...